سیویلیکا را در شبکه های اجتماعی دنبال نمایید.

A Recombinant Monospecific Anti‑PLGF Bivalent Nanobody for Angiogenesis Targeting

Publish Year: 1399
Type: Conference paper
Language: English
View: 229
این Paper فقط به صورت چکیده توسط دبیرخانه ارسال شده است و فایل کامل قابل دریافت نیست. برای یافتن Papers دارای فایل کامل، از بخش [جستجوی مقالات فارسی] اقدام فرمایید.

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

Export:

Link to this Paper:

Document National Code:

MSEMSMED14_013

Index date: 14 November 2021

A Recombinant Monospecific Anti‑PLGF Bivalent Nanobody for Angiogenesis Targeting abstract

Background and Objective: During the past two decades, tumor therapy based on monoclonal antibody has been found as a confident therapeutic approach in solid tumors and hematologic malignancies. Nanobodies are the smallest fragment of an antigen-binding domain in heavy chain-only antibody originated from the Camelidae family. Accordingly, they are being recently developed rapidly as diagnostic and therapeutic agents. In this regard, targeting of angiogenic factors like Placenta growth factor (PLGF) via nanobodies show a high effectiveness.Materials and Methods: In the current study, we developed a recombinant anti-PLGF bivalent nanobody based on the affinity enhancement mutant form of anti-PLGF nanobody to suppress the angiogenesis progression. Thereafter, the bivalent nanobody (bi-Nb) was cloned and then expressed into a bacterial system. Afterward, the purity was authorized using western blot assay and the affinity was assessed using ELISA. In this regard, proliferation, 3D capillary tube formation, and migration assays were employed as functional assays. The obtained data were analyzed using t-test and P < 0.05 was considered as statistically significant Findings: The results indicated that the bivalent nanobody could inhibit proliferation, mobility, and formation of endothelial cell capillary-like structure. Moreover, the EC50 was estimated for endothelial cell proliferation and capillary tube formation to be about 100 ng/ml and 65 ng/ml, respectively. Migration of MCF-7 was inhibited as about 69%, rather than the control. Conclusion: Accumulation of data have shown that targeting of angiogenic factors like VEGF via monoclonal antibodies or nanobodies can be useful in the suppression of tumor progression. Also, the inhibition of PLGF with monoclonal antibody indicated that it is significant in angiogenesis suppression. However, due to the intrinsic properties of nanobodies, they are suggested to be used. Since the small size is rapidly removed through the liver or kidney system, so it is important to use bivalent or polymeric forms for extending the halflife.Our findings indicated that the inhibition of PLGF can prevent the growth and proliferation of endothelial cells and tumor cells through the bivalent nanobody. So, it is suggested as a novel therapeutic agent for angiogenesis suppression.

A Recombinant Monospecific Anti‑PLGF Bivalent Nanobody for Angiogenesis Targeting Keywords:

A Recombinant Monospecific Anti‑PLGF Bivalent Nanobody for Angiogenesis Targeting authors

Abolfazl Nikooharf

Department of Medical Biotechnology and Molecular Science, North Khorasan University of Medical Science, Bojnurd, Iran

Roghaye Arezumand

Department of Medical Biotechnology and Molecular Science, North Khorasan University of Medical Science, Bojnurd, Iran